California Statutes

§ 123707. — 123707. (Amended by Stats. 2004, Ch. 228, Sec. 6.)

California § 123707.
JurisdictionCalifornia
Code HSCHealth and Safety Code - HSC
Div. 106.DIVISION 106. PERSONAL HEALTH CARE (INCLUDING MATERNAL, CHILD, AND ADOLESCENT)
Part 2.PART 2. MATERNAL, CHILD, AND ADOLESCENT HEALTH
Ch. 3.CHAPTER 3. Child Health
Art. 2.5.ARTICLE 2.5. Infant Botulism Treatment and Prevention Program

This text of California § 123707. (123707. (Amended by Stats. 2004, Ch. 228, Sec. 6.)) is published on Counsel Stack Legal Research, covering California primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Cal. Health and Safety Code - HSC Code § 123707. (2026).

Text

(a)The State Department of Health Services may manufacture, test, distribute, and maintain licensure of the product Botulism Immune Globulin Intravenous (Human) if all necessary federal licenses are obtained. The department was issued United States License No. 1622 on October 23, 2003, by the United States Food and Drug Administration under the authority of Section 351(a) of the Public Health Service Act controlling the manufacture and sale of biological products. The product may be labeled with the proprietary name BabyBIG®.
(b)The United States Food and Drug Administration license agreement stipulated the contracts and commodity purchases required to manufacture, test, distribute, and maintain licensure of Botulism Immune Globulin Intravenous (Human). Therefore, contracts and commod

Free access — add to your briefcase to read the full text and ask questions with AI

Legislative History

Amended by Stats. 2004, Ch. 228, Sec. 6. Effective August 16, 2004.
View on official source ↗

Cite This Page — Counsel Stack

Bluebook (online)
California § 123707., Counsel Stack Legal Research, https://law.counselstack.com/statute/ca/HSC/123707..